Get alerted on the PharmaSources E-Newsletter and Pharma Sources Insight E-Compilation!
Note: You can unsubscribe from the alerts at any time.
Advertising

EOM Pharmaceuticals Announces First Patients Dosed In R1: RESCUE Phase 1/2a Open-label Trial Evaluating EOM613 In Hospitalized COVID-19 Patients With Severe Symptoms In Brazil

prnewswireAugust 25, 2021

Tag: EOM Pharmaceuticals , EOM613 , COVID-19

PharmaSources Customer Service